Ingjerd Sæves holds a M.Sc. degree in pharmacy (Cand.pharm) from the University of Oslo in 2007. She finished her Ph.D. in 2013, working primarily with pharmacokinetics of immunosuppressant drug in liver transplanted patients, with a special focus on possible individualization of glucocorticoid therapy. Since 2012 she has been working at the Department of Newborn Screening at Oslo University Hospital as a scientist and head engineer, with responsibility for the mass spectrometry analyses in the routine screening and for research use. Recent research has focused on projects related to the identification of new biomarkers and candidate diseases for newborn screening, as well as ways to improve and develop the present screening panel.